The Supplemental New Drug Application is Based on Positive Results from Global Randomized Phase 2 Study in Infants…
BioMarin
Did you know that more than 90% of rare diseases are still without an FDA-approved treatment? On November 19, 2021, the U.S.…
BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration to Expand Label to Treat Children…
April 25, 2022
The Perfect Date: National DNA Day
The perfect date: April 25th…because it’s not too hot, not too cold. All you need is a light…
SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug…
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in Europe…
Established in 2018, The Chandler Project provides advocacy, awareness, research and support to those affected by achondroplasia, the most common form of dwarfism, and other skeletal dysplasias. TCP hosts the only event in North Amercia that brings together members of the skeletal dysplasia community physicians, researchers, biotech industries and more together at the annual Achondroplasia + Skeletal Dysplasia Research Conference.